Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study

• Published in: Advances in therapy 2024-04, Vol.41 (4), p.1419-1435
• Main Authors: Alharbi, Adel, Yousef, Abdullah, Zubani, Amal, Alzahrani, Mohammad, Al-Hindi, Mohammad, Alharbi, Saleh, Alahmadi, Turki, Alabdulkarim, Hana, Kazmierska, Paulina, Beuvelet, Matthieu
• Format: Article
• Language: English
• Subjects: Antiviral Agents - therapeutic use; Cardiology; Child; Endocrinology; Hospitalization; Humans; Infant; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Respiratory Sounds; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus Infections - prevention & control; Respiratory Syncytial Viruses; Rheumatology; Saudi Arabia - epidemiology
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-024-02798-w

Introduction Respiratory syncytial virus (RSV) represents a considerable burden on the healthcare system and hospital resources. This study explored the impact of universal immunoprophylaxis with long-acting monoclonal antibody (nirsevimab) during infants’ first RSV season on RSV-induced health events and related costs in the Kingdom of Saudi Arabia (KSA). Methods The burden of RSV-induced health events and related costs under the current standard of practice (SoP) and the impact of universal immunoprophylaxis with nirsevimab was estimated using a static decision-analytic model in a cohort of infants experiencing their first RSV season in the KSA. The model estimated hospital admissions (including pediatric intensive care unit [PICU] admissions and mechanical ventilation [MV]), emergency room (ER) visits, primary care (PC) visits, long-term sequelae, and RSV mortality. Results The model estimated that under the current SoP, RSV results in 17,179–19,607 hospitalizations (including 2932–3625 PICU and 172–525 MV admissions), 57,654–191,115 ER visits, 219,053–219,970 PC visits, 14 deaths, 12,884–14,705 cases of recurrent wheezing, and a total cost of SAR 480–619 million. Universal nirsevimab immunoprophylaxis was estimated to avert 58% of hospitalizations (58% PICU admissions, 58% MV episodes), 53% of ER visits, 53% of PC visits, 58% of episodes of recurrent wheezing, 8 deaths, and result in savings of SAR 274–343 million in total healthcare cost. Conclusion Compared with current SoP, an nirsevimab immunoprophylaxis strategy in the KSA for all infants during their first RSV season was estimated to dramatically decrease healthcare resource use, and economic burden associated with RSV.